The abstract is read at the publisher; the summary is JClub's.
RHOA loss in large B-cell lymphomas downregulates CD19 and promotes CAR-19 T-cell resistance, with RHOA deficiency present in one in six newly diagnosed cases.
- Why it matters: Durable responses to CD19 CAR T cells occur in fewer than half of patients, and the mechanisms behind frequent RHOA deletions in newly diagnosed disease are unclear.
- What they did: The study tested RHOA-deficient lymphoma cells for CD19 levels and CAR-19 T-cell sensitivity in vitro and in vivo, then used single-cell profiling of immunocompetent RHOA-deficient lymphoma microenvironments.
- The result: Although interferon gamma production increased, RHOA-deficient tumor cells showed impaired cytokine responsiveness, including failed induction of class I MHC molecules, and single-cell features matched CAR-19-resistant patients.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.